ArticleAntimicrobial agents and chemotherapy2000
Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in anAntimicrobial agents and chemotherapy · 2024Article
- Phage Therapy, a Salvage Treatment for Multidrug-Resistant Bacteria Causing Infective Endocarditis.Biomedicines · 2023Review
- Activity of the Lactate Dehydrogenase Inhibitor Oxamic Acid against the Fermentative BacteriumAntibiotics (Basel, Switzerland) · 2022Article
- Models for Gut-Mediated Horizontal Gene Transfer by Bacterial Plasmid Conjugation.Frontiers in microbiology · 2022Review
- A Combined Phenotypic-Genotypic Predictive Algorithm for In Vitro Detection of Bicarbonate: β-Lactam Sensitization among Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Bacterial biofilms in infective endocarditis: an in vitro model to investigate emerging technologies of antimicrobial cardiovascular device coatings.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Article
- Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome.Frontiers in cell and developmental biology · 2021Review
- Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in anAntimicrobial agents and chemotherapy · 2020Article
- Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium.The Journal of infectious diseases · 2020Article
- Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitisAntimicrobial agents and chemotherapy · 2019Article
- Evaluation of Phage Therapy in the Context ofViruses · 2019Review
- Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.Antimicrobial agents and chemotherapy · 2018Article
- An in vitro proof-of-principle study of sonobactericide.Scientific reports · 2018Article
- Defeating Antibiotic- and Phage-ResistantFrontiers in microbiology · 2018Article
- Review
- Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).The Journal of antimicrobial chemotherapy · 2017Article
- Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing.BMJ case reports · 2016Article
- Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.Antimicrobial agents and chemotherapy · 2014Article
- Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.Antimicrobial agents and chemotherapy · 2014Article
- Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Animal models are commonly used to determine the efficacy of various antimicrobial agents for treatment of bacterial endocarditis. Previously we have utilized an in vitro infection model, which incorporates simulated endocardial vegetations (SEVs) to evaluate the pharmacodynamics of various antibiotics. In the present study, we compared four experimental rabbit endocarditis protocols to an in vitro infection model in an effort to determine if these models are comparable. We have evaluated the activity of clinafloxacin, trovafloxacin, sparfloxacin, and ciprofloxacin in rabbit models against Staphylococcus aureus and Enterococcus spp. In vitro models were performed simulating the antibiotic pharmacokinetics obtained in the in vivo studies. Models were dosed the same as rabbit models, and SEVs were evaluated at the same time the rabbit vegetations were examined. Clinafloxacin and trovafloxacin were evaluated against methicillin-susceptible (MSSA1199) and -resistant (MRSA494) strains of S. aureus. Ciprofloxacin was studied against MSSA1199 and MSSA487. Sparfloxacin and clinafloxacin were evaluated against Enterococcus faecium SF2149 and Enterococcus faecalis WH245, respectively. We found that reductions in SEV bacterial density obtained in the in vitro model were similar to those obtained in rabbit vegetations, indicating that the SEV model may be a valuable tool for assessing antibiotic potential in the treatment of bacterial endocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.